The 36-month beta value for ATAI is at 0.93. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 115.49M, and currently, shorts hold a 4.81% of that float. The average trading volume for ATAI on April 24, 2024 was 1.63M shares.
ATAI) stock’s latest price update
The stock of ATAI Life Sciences N.V. (NASDAQ: ATAI) has decreased by -4.82 when compared to last closing price of 1.97.Despite this, the company has seen a loss of -5.30% in its stock price over the last five trading days. Proactive Investors reported 2024-04-24 that atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its Phase 2a study of its novel intranasal 5-MeO-MDT drug candidate BPL-003 in treatment-resistant depression. Initial results from the first part of the study unveiled in March showed that a single dose of BPL-003 was safe and well-tolerated and had a “rapid and durable” antidepressant effect which lasted up to 12 weeks.
ATAI’s Market Performance
ATAI’s stock has fallen by -5.30% in the past week, with a monthly rise of 12.95% and a quarterly rise of 7.76%. The volatility ratio for the week is 8.46% while the volatility levels for the last 30 days are 11.07% for ATAI Life Sciences N.V. The simple moving average for the last 20 days is -11.89% for ATAI’s stock, with a simple moving average of 14.39% for the last 200 days.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with Maxim Group repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to Maxim Group is $6 based on the research report published on April 03, 2024 of the current year 2024.
Loop Capital, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $18. The rating they have provided for ATAI stocks is “Buy” according to the report published on November 01st, 2022.
Maxim Group gave a rating of “Buy” to ATAI, setting the target price at $25 in the report published on November 30th of the previous year.
ATAI Trading at -4.99% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.21% of loss for the given period.
Volatility was left at 11.07%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares surge +8.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, ATAI fell by -5.05%, which changed the moving average for the period of 200-days by -16.07% in comparison to the 20-day moving average, which settled at $2.1355. In addition, ATAI Life Sciences N.V. saw 32.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from Rao Srinivas, who sale 61,640 shares at the price of $1.85 back on Apr 02 ’24. After this action, Rao Srinivas now owns 113,360 shares of ATAI Life Sciences N.V., valued at $114,034 using the latest closing price.
Kirpekar Sahil, the Chief Business Officer of ATAI Life Sciences N.V., sale 35,801 shares at $1.85 during a trade that took place back on Apr 02 ’24, which means that Kirpekar Sahil is holding 64,199 shares at $66,232 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -397.42 for the present operating margin
- -0.71 for the gross margin
The net margin for ATAI Life Sciences N.V. stands at -128.7. The total capital return value is set at -0.46. Equity return is now at value -15.97, with -13.43 for asset returns.
Based on ATAI Life Sciences N.V. (ATAI), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.38. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -46.97.
Currently, EBITDA for the company is -125.15 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 908.38. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.22.
Conclusion
In conclusion, ATAI Life Sciences N.V. (ATAI) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
